Summary
TLIS Chart
Why Is Talis Biomedical (TLIS) Stock Down 52% Today?
Talis Biomedical (NASDAQ: TLIS ) stock is falling on Wednesday after the company provided investors with an update on its restructuring plans. Talis Biomedical has brought on two new board members in Patricia Ferrari and John Young, Jr. These two have also elected to serve on a special committee focused on the restructuring of the company.
Talis Biomedical Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 David Einhorn Greenlight Capital Re Ltd. | 149,052 | $860,030 | $860,030 | - | - |
Talis Biomedical Corporation (TLIS) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Talis Biomedical Corporation Profile
| Health Care Technology Industry | Healthcare Sector | Rebecca Markovich CEO | OTC PINK Exchange | 87424L108 CUSIP |
| US Country | 99 Employees | - Last Dividend | 6 Jul 2023 Last Split | 12 Feb 2021 IPO Date |
Overview
Talis Biomedical Corporation is a pioneering molecular diagnostic company focused on the development of innovative testing solutions for infectious diseases through its advanced Talis One system. Officially incorporated in 2013, the company aims at overcoming the limitations associated with current point-of-care diagnostic technologies. With its headquarters located in Redwood, California, Talis Biomedical is at the forefront of creating accessible and reliable diagnostic testing, emphasizing the importance of quick and accurate diagnostics in managing infectious diseases effectively.
Products and Services
- Talis One system
The Talis One system represents the core of Talis Biomedical Corporation's product line, designed to enhance the diagnostic capabilities of healthcare providers at the point of care. The system is tailored for addressing the critical needs in infectious disease diagnosis by offering a platform that delivers fast, reliable, and convenient testing experiences. This innovation is aimed at transforming the landscape of infectious disease management by making diagnostic testing more accessible and efficient.
- Talis One tests for respiratory infections
Part of the expanding suite of diagnostic tests, the Talis One tests for respiratory infections are crafted to deliver precise and swift detection of conditions impacting the respiratory system. These tests underscore the company's commitment to tackling the prevalent challenge of respiratory diseases, providing tools designed to aid in the timely diagnosis and treatment of patients.
- Talis One tests for infections related to women's health and sexually transmitted infections
Emphasizing the importance of women's health and the rising concern of sexually transmitted infections (STIs), Talis Biomedical offers dedicated tests within the Talis One system. These tests are developed to offer secure, accurate, and swift diagnostics, aiming to address the unique healthcare needs in women's health and STIs effectively. This move is in line with the company's mission to broaden its impact on public health by focusing on areas of significant concern and need.
- Other tests for various respiratory infections, including a respiratory panel test
Complementing its product range, Talis Biomedical is also developing additional tests focusing on a wider spectrum of respiratory infections. This includes a comprehensive respiratory panel test capable of detecting influenza A and influenza B viruses, among others. This expansion reiterates the company's dedication to covering a broad array of infectious diseases, thereby enhancing its position as a comprehensive provider of diagnostic solutions.
